PHARMACOLOGY

PAPER – I

PHARM/D/16/34/I

Time : 3 hours Max. Marks :100

Important instructions:

- Attempt all questions in order.
- Each question carries 10 marks. •
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together. ٠
- Start the answer to a question on a fresh page or leave adequate space between two answers. •
- Draw table/diagrams/flowcharts wherever appropriate •

		<i>table/diagrams/flowcharts wherever appropriate.</i> Nort notes on:	
1.		Define bioavailability and its clinical relevance. Compare and contrast between bioequivalence and therapeutic equivalence.	5+5
2.		What is High Throughput Screening in drug development? Experimental screening methods for potential anti- arrhythmic activity of New Chemical Entity (NCE).	5+5
3.	a)	Compare and contrast between Therapeutic Index and Therapeutic Window.	5+(2+3)
	b)	Factors influencing first pass metabolism of drugs and therapeutic implication of this phenomenon.	
4.	a)	Which are the sampling errors in drug screening program?	2+3+5
		What is the impact of sampling errors? Enumerate the ways of reducing these errors.	
5.		Principle of spectrometry technique. Its utility in clinical practice with suitable examples.	5+5
6.	b)	Define pA ₂ value. Method of determination of pA ₂ value. Applications of pA ₂ determination.	2+4+4
7.		Targeted drug delivery. Its utility in clinical practice.	5+5
8.	b)	Define chronopharmacology. Aims of chronopharmacology. Utility of chronopharmacology in clinical practice.	2+3+5
9.	b)	Define Good Clinical Practice (GCP) in drug development. What are the principles of GCP? Enumerate advantages of GCP.	2+4+4
10.		ABC transporters. Clinical relevance of these transporters.	5+5